21 research outputs found
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
[Background]: Smoldering multiple myeloma (SMM) is a heterogeneous disease in terms of progression to myeloma (MM), but its standard of care continues to be observation.
[Methods]: The QuiRedex phase 3 trial initiated in 2007 included 119 high-risk patients with SMM randomized to treatment or observation. Treatment consisted of nine 4-week induction cycles (lenalidomide [Rd], 25 mg on days 1–21 plus dexamethasone, 20 mg on days 1–4 and 12–15), followed by maintenance (R, 10 mg on days 1–21) for up to 2 years. The primary end-point was time to progression (TTP) to myeloma based on per protocol population. Secondary end-points were overall survival (OS), response rate, and safety. An update of the trial after a long-term follow-up is presented here. This trial was registered with ClinicalTrials.gov (NCT00480363).
[Findings]: After a median follow-up time of 12.5 years (range: 10.4–13.6), the median TTP to MM was 2.1 years in the observation arm and 9.5 years in the Rd arm (HR: 0.28, 95% CI: 0.18–0.44, p < 0.0001). The median OS was 8.5 years in the abstention arm and not reached in the Rd group (HR: 0.57, 95% CI: 0.34–0.95, p = 0.032). Patients who progressed received optimized treatments according to the standards of care, and the OS from progression was comparable in both arms (p = 0.96).
[Interpretation]: This analysis confirms that early treatment with Rd for high-risk SMM translates into a sustained benefit in both TTP and OS.This study was also supported by the Cooperative Research Thematic Network grant RD12/0036/0058 and RD12/0036/0046 and Instituto de Salud Carlos III/SubdirecciĂłn General de InvestigaciĂłn Sanitaria, Spain. (FIS:PI12/02311/01761/01569)
Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma
Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and
refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access
to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory
multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16mg/kg) was administered to 73 patients who had ≥3
prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The
median duration of daratumumab treatment was 3.3 (range: 0.03–13.17) months, with a median number of 12 (range: 1–25)
infusions. Grade 3/4 treatment-emergent adverse events were reported in 74% of patients and included lymphopenia (28.8%),
thrombocytopenia (27.4%), neutropenia (21.9%), leukopenia (19.2%), and anemia (15.1%). Common (>5%) serious treatmentemergent adverse events included respiratory tract infection (9.6%), general physical health deterioration (6.8%), and back pain
(5.5%). Infusion-related reactions occurred in 45% of patients. The median change from baseline in all domains of the EQ-5D-5L and
EORTC QLQ-C30 was mostly 0. A total of 18 (24.7%) patients achieved a partial response or better, with 10 (13.7%) patients
achieving a very good partial response or better. Median progression-free survival was 3.98 months. The results of this early access
treatment protocol are consistent with previously reported trials of daratumumab monotherapy and confirm its safety and antitumoral
efficacy in Spanish patients with heavily treated relapsed or refractory multiple myeloma
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple
myeloma are required. One strategy is to combine melphalan and prednisone with novel agents.
We previously reported an 89% response rate, including 32% complete responses and 11% near
complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP)
in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report
updated time-to-events data and the impact of poor prognosis factors on outcome
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (N = 94), MGUS (N = 20) and multiple myeloma (MM, N = 52) vs. healthy adults (N = 30). MFC detected clonality in virtually all AL amyloidosis (99%) patients. Furthermore, we developed an automated risk-stratification system based on BMPCs features, with independent prognostic impact on progression-free and overall survival of AL amyloidosis patients (hazard ratio: ≥ 2.9;P ≤ .03). Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUC = 0.74;P < .001), and might potentially be used as biomarkers for the identification of MGUS and MM patients, who are candidates for monitoring pre-symptomatic organ damage related to AL amyloidosis. Altogether, this study addressed the need for consensus on how to use flow cytometry in AL amyloidosis, and proposes a standardized MFC-based automated risk classification ready for implementation in clinical practice
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM). Thus, characterization of the minor MRD subclone may represent a unique model to understand chemoresistance, but to our knowledge, the phenotypic and genetic features of the MRD subclone have never been investigated. Here, we compared the antigenic profile of MRD vs diagnostic clonal PCs in 40 elderly MM patients enrolled in the GEM2010MAS65 study and showed that the MRD subclone is enriched in cells overexpressing integrins (CD11a/CD11c/CD29/CD49d/CD49e), chemokine receptors (CXCR4), and adhesion molecules (CD44/CD54). Genetic profiling of MRD vs diagnostic PCs was performed in 12 patients; 3 of them showed identical copy number alterations (CNAs), in another 3 cases, MRD clonal PCs displayed all genetic alterations detected at diagnosis plus additional CNAs that emerged at the MRD stage, whereas in the remaining 6 patients, there were CNAs present at diagnosis that were undetectable in MRD clonal PCs, but also a selected number of genetic alterations that became apparent only at the MRD stage. The MRD subclone showed significant downregulation of genes related to protein processing in endoplasmic reticulum, as well as novel deregulated genes such as ALCAM that is prognostically relevant in MM and may identify chemoresistant PCs in vitro. Altogether, our results suggest that therapy-induced clonal selection could be already present at the MRD stage, where chemoresistant PCs show a singular phenotypic signature that may result from the persistence of clones with different genetic and gene expression profiles. This trial was registered at www.clinicaltrials.gov as #NCT01237249
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Purpose
To perform a critical analysis on the impact of depth of response in newly diagnosed multiple
myeloma (MM).
Patients and Methods
Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma)
2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical
trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months
after study enrollment. Median follow-up of the series was 71 months.
Results
Achievement of complete remission (CR) in the absence of MRD negativity was not associated with
prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial
response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months,
respectively). MRD-negative status was strongly associated with prolonged PFS (median,
63 months; P , .001) and OS (median not reached; P , .001) overall and in subgroups defined by
prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity
versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics
showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to
CR) for response assessment. Superior MRD-negative rates after different induction regimens
anticipated prolonged PFS. Among 34 MRD-negative patients withMMand a phenotypic pattern of
bone marrow involvement similar to monoclonal gammopathy of undetermined significance at
diagnosis, the probability of “operational cure” was high; median PFS was 12 years, and the 10-year
OS rate was 94%.
Conclusion
Our results demonstrate that MRD-negative status surpasses the prognostic value of CR
achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or
patient risk group. MRD negativity should be considered as one of the most relevant end points for
transplant-eligible and elderly fit patients with MM
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p < 0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p < 0.0001) and a shorter survival in MM patients with active disease requiring treatment (p <= 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
[EN]Fluorescence in situ hybridization (FISH) has become a powerful technique for prognostic assessment in multiple myeloma
(MM). However, the existence of associations between cytogenetic abnormalities compels us to re-assess the value of each
abnormality. A total of 260 patients with MM at the time of
diagnosis, enrolled in the GEM-2000 Spanish transplant protocol, have been analyzed by FISH in order to ascertain the
independent influence on myeloma prognosis of IGH translocations, as well as RB and P53 deletions. Survival analyses
showed that patients with t(4;14), RB or P53 deletions had a
significantly shorter survival than patients without these
abnormalities. However, patients with RB deletions without
other abnormalities in FISH analysis, displayed a similar
outcome to those patients without genetic changes by FISH
(46 vs 54 months, P ÂĽ 0.3). In the multivariate analysis the
presence of t(4;14), RB deletion associated with other abnormalities, age 460 years, high proportion of S-phase cells and
advanced stage of the disease according to the International
Staging System retained their independent prognostic influence. In summary, RB deletion as a sole abnormality does not
lead to a shortening in the survival of MM patients, whereas
t(4;14) confers the worst prognosis in MM patients treated with
high-dose chemotherapy